Literature DB >> 1728251

Chromosome fragility and psychopathology in obligate female carriers of the fragile X chromosome.

L S Freund1, A L Reiss, R Hagerman, S Vinogradov.   

Abstract

The relationship between fragility (the percentage of cells exhibiting the fragile X chromosome abnormality) and psychopathological conditions was investigated in a sample of 40 obligate female carriers of the fragile X chromosome. Subjects were categorized by those with positive fragility greater than 0% (n = 19) and those with 0% fragility (n = 21). Compared with women with 0% fragility, it was expected that women with positive fragility would have a higher likelihood of manifesting a spectrum of social and psychological disability previously shown to be associated with fragile X syndrome in women. It was also expected that within the group with positive fragility, degree of fragility would be related to severity of symptoms. Results partially supported the hypotheses: women with fragility over 0% were more likely to be assigned a diagnosis of schizotypal features, were rated higher on symptoms associated with the schizophrenia spectrum, and scored lower on IQ, level of healthiest functioning, education, and socioeconomic status than women with 0% fragility. Subsequent comparisons with a control group indicated that the group with 0% fragility and normal controls did not differ on these variables. Within the group with positive fragility, increasing fragility was related to greater severity of symptoms and lower IQ, education, socioeconomic status, and levels of adaptive functioning, as predicted. Contrary to expectations, positive fragility was not associated with proportion of affective disorder diagnoses or ratings on affective disorder symptoms. The results of the study provide evidence that degree of fragility is a potentially important predictor of psychopathology among women with normal IQ who are carriers of the fragile X chromosome abnormality.

Entities:  

Mesh:

Year:  1992        PMID: 1728251     DOI: 10.1001/archpsyc.1992.01820010054007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

Review 1.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

2.  Social functioning among girls with fragile X or Turner syndrome and their sisters.

Authors:  M M Mazzocco; T Baumgardner; L S Freund; A L Reiss
Journal:  J Autism Dev Disord       Date:  1998-12

Review 3.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

4.  Fragile X syndrome.

Authors:  J Turk
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

5.  Neurobehavioral effects of the fragile X premutation in adult women: a controlled study.

Authors:  A L Reiss; L Freund; M T Abrams; C Boehm; H Kazazian
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

6.  Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders.

Authors:  Allyn McConkie-Rosell; Liane Abrams; Brenda Finucane; Amy Cronister; Louise W Gane; Sarah M Coffey; Stephanie Sherman; Lawrence M Nelson; Elizabeth Berry-Kravis; David Hessl; Sufen Chiu; Natalie Street; Ajay Vatave; Randi J Hagerman
Journal:  J Genet Couns       Date:  2007-05-12       Impact factor: 2.537

7.  Chromosome fragile sites in mentally retarded males: increased incidence with seizures and diphenylhydantoin therapy.

Authors:  K B Hodges; R S Larson; M G Butler
Journal:  Ann Clin Lab Sci       Date:  1998 Sep-Oct       Impact factor: 1.256

8.  Developmental malformation of the corpus callosum: a review of typical callosal development and examples of developmental disorders with callosal involvement.

Authors:  Lynn K Paul
Journal:  J Neurodev Disord       Date:  2010-09-23       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.